专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2002088317A3 FUSION MOLECULES AND METHODS FOR TREATMENT OF IMMUNE DISEASES 审中-公开
公开(公告)号：WO2002088317A3
公开(公告)日：2002-11-07
申请号：PCT/US2002/013527
申请日：2002-05-01
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , SAXON, Andrew , ZHANG, Ke , ZHU, Daocheng
发明人： SAXON, Andrew , ZHANG, Ke , ZHU, Daocheng
IPC分类号： A61K39/00
摘要： The invention concerns bifunctional fusion molecules, and novel, safer and more efficacious methods for the treatment of immune disorders resulting from excessive or unwanted immune responses. The invention provides methods for the suppression of type I hypersensitive (i.e., IgE-mediated) allergic conditions, methods for the prevention of anaphylactic responses that occur as a result of traditional peptide immunotherapies for allergic and autoimmune disorders, and provides novel methods for the treatment of autoimmune conditions, where the methods have reduced risk of triggering an anaphylactic response. The invention provides novel therapeutic approaches for the treatment of allergic responses, including the prevention of anaphylactic response that can occur from environmental allergen exposure. The invention also provides methods for the treatment of autoimmune disorders such as multiple sclerosis, autoimmune type I diabetes mellitus, and rheumatoid arthritis. The invention also provides methods for preventing anaphylactic response during traditional antigen therapies.

2. 发明申请

WO2006083964A2 MODIFIED FUSION MOLECULES FOR TREATMENT OF ALLERGIC DISEASE 审中-公开
标题翻译：用于治疗过敏性疾病的改良融合分子
公开(公告)号：WO2006083964A2
公开(公告)日：2006-08-10
申请号：PCT/US2006/003562
申请日：2006-01-31
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , SAXON, Andrew , ZHANG, Ke , ZHU, Daocheng
发明人： SAXON, Andrew , ZHANG, Ke , ZHU, Daocheng
IPC分类号： A61K39/395 , C07H21/04 , C12P21/06 , C07K16/42
CPC分类号： C07K16/00 , C07K2317/52 , C07K2319/30 , Y10S530/866 , Y10S530/868
摘要： The present invention comprises a fusion molecule comprising a Fee fragment sequenc including functionally active CH2, CH3 and CH4 domains of the constant region of an IgE heavy chain (CHe2-CHe3-CHe4 sequence) linked at its C-terminus to the N-terminus of a second polypeptide including functionally active hinge, CH2 and CH3 domains of the constant region of an IgG 1 heavy chain (γhinge-CHγ2-CHγ3 sequence), pharmaceutical compositions comprising the fusion molecule and methods of treatment using the fusion molecule.
摘要翻译：本发明包括融合分子，其包含费用片段序列，其包含在其C末端至N-末端连接的IgE重链（CHe2-CHe3-CHe4序列）恒定区的功能活性CH 2，CH 3和CH 4结构域包含IgG1重链（α铰链-CH2-CH2→3序列）恒定区的功能活性铰链，CH2和CH3结构域的第二多肽，包含融合分子的药物组合物和使用融合分子的治疗方法。

3. 发明申请

WO2002088317A2 FUSION MOLECULES AND METHODS FOR TREATMENT OF IMMUNE DISEASES 审中-公开
标题翻译：融合分子和治疗免疫缺陷病的方法
公开(公告)号：WO2002088317A2
公开(公告)日：2002-11-07
申请号：PCT/US2002/013527
申请日：2002-05-01
申请人： REGENTS OF THE UNIVERSITY OF CALIFORNIA , SAXON, Andrew , ZHANG, Ke , ZHU, Daocheng
发明人： SAXON, Andrew , ZHANG, Ke , ZHU, Daocheng
IPC分类号： C12N
CPC分类号： C07K16/00 , A61K2039/505 , C07K2317/52 , C07K2319/00
摘要： The invention concerns bifunctional fusion molecules, and novel, safer and more efficacious methods for the treatment of immune disorders resulting from excessive or unwanted immune responses. The invention provides methods for the suppression of type I hypersensitive (i.e., IgE-mediated) allergic conditions, methods for the prevention of anaphylactic responses that occur as a result of traditional peptide immunotherapies for allergic and autoimmune disorders, and provides novel methods for the treatment of autoimmune conditions, where the methods have reduced risk of triggering an anaphylactic response. The invention provides novel therapeutic approaches for the treatment of allergic responses, including the prevention of anaphylactic response that can occur from environmental allergen exposure. The invention also provides methods for the treatment of autoimmune disorders such as multiple sclerosis, autoimmune type I diabetes mellitus, and rheumatoid arthritis. The invention also provides methods for preventing anaphylactic response during traditional antigen therapies.
摘要翻译：本发明涉及双功能融合分子，以及用于治疗由过度或不需要的免疫应答引起的免疫疾病的新型，更安全和更有效的方法。本发明提供抑制I型过敏（即IgE介导的）变态反应病症的方法，用于预防因过敏性和自身免疫性疾病的传统肽免疫治疗而发生的过敏反应的方法，并提供新的治疗方法的自身免疫病症，其中方法降低了触发过敏反应的风险。本发明提供了用于治疗过敏反应的新型治疗方法，包括预防由环境变应原暴露引起的过敏反应。本发明还提供了治疗自身免疫性疾病如多发性硬化，自身免疫性I型糖尿病和类风湿性关节炎的方法。本发明还提供了用于在传统抗原治疗期间预防过敏反应的方法。

4. 发明申请

WO2007123771A2 IGE DIRECTED DNA VACCINATION 审中-公开
标题翻译： IGE指导DNA疫苗接种
公开(公告)号：WO2007123771A2
公开(公告)日：2007-11-01
申请号：PCT/US2007/008028
申请日：2007-03-30
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , ZHANG, Ke , SAXON, Andrew
发明人： ZHANG, Ke , SAXON, Andrew
IPC分类号： A61K47/48 , C07K16/00 , C12N15/87
CPC分类号： C07K16/00 , A01K2267/03 , A61K39/00 , A61K47/6455 , A61K47/646 , A61K47/6807 , A61K47/6883 , A61K2039/53 , C07K2319/30 , C07K2319/33 , C07K2319/80 , C12N15/87
摘要： This invention is directed to a novel approach for focusing and expressing DNA vaccinates in Antigen Presenting Cells (APCs) mediated through targeting IgE receptors (FcεRs) on APC and driving DNA expression through provision of an APC specific regulatory element This vaccine can be used in the prevention or treatment of allergic disease.
摘要翻译：本发明涉及一种用于在APC上靶向IgE受体（FceR）介导的抗原呈递细胞（APC）中聚焦和表达DNA接种的新方法，并通过提供APC特异性调节元件驱动DNA表达。该疫苗可用于预防或治疗过敏性疾病。

5. 发明申请

WO2002059136A9 IMMUNOGLOBULIN CLASS SWITCH RECOMBINATION 审中-公开
公开(公告)号：WO2002059136A9
公开(公告)日：2002-08-01
申请号：PCT/US2002/005006
申请日：2002-01-15
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , SAXON, Andrew , ZHANG, Ke
发明人： SAXON, Andrew , ZHANG, Ke
IPC分类号： C07H21/02 , C07H21/04 , C12N5/10 , C12N15/13 , C12N15/63 , C12Q1/68

6. 发明申请

WO2002059136A2 IMMUNOGLOBULIN CLASS SWITCH RECOMBINATION 审中-公开
标题翻译：免疫球蛋白类开关重组
公开(公告)号：WO2002059136A2
公开(公告)日：2002-08-01
申请号：PCT/US2002/005006
申请日：2002-01-15
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , SAXON, Andrew , ZHANG, Ke
发明人： SAXON, Andrew , ZHANG, Ke
IPC分类号： C07H
CPC分类号： C12N15/1034 , C12N15/63 , C12N15/85 , C12N2830/002 , C12N2830/85 , C12N2840/203 , C12N2840/44 , C12Q1/6897
摘要： This invention concerns class switch recombination (CSR) substrates and assays that permit dissection of the mechanisms involved in CSR and are powerful tools in drug discovery.
摘要翻译：本发明涉及类交换重组（CSR）底物和允许解剖参与CSR的机制的测定法，并且是药物发现中的强大工具。

7. 发明申请

WO2015013668A1 ANTI-IMMUNOGLOBULIN E ANTIBODIES AND METHODS OF USE THEREOF 审中-公开
标题翻译：抗体免疫球蛋白E抗体及其使用方法
公开(公告)号：WO2015013668A1
公开(公告)日：2015-01-29
申请号：PCT/US2014/048284
申请日：2014-07-25
申请人： ZHANG, Ke , SAXON, Andrew
发明人： ZHANG, Ke , SAXON, Andrew
IPC分类号： C07K16/42 , A61K39/395 , A61P37/08
CPC分类号： C07K16/4291 , A61K2039/505 , C07K2317/24 , C07K2317/76 , C07K2317/77 , C07K2317/92
摘要： The present disclosure provides antibodies that specifically bind to circulating and receptor-bound IgE and inhibit IgE-mediated cell activation. The antibodies find use in various treatment, diagnostic, and monitoring applications, which are also provided.
摘要翻译：本公开提供了特异性结合循环和受体结合的IgE并抑制IgE介导的细胞活化的抗体。抗体可用于各种治疗，诊断和监测应用，这些也被提供。

8. 发明申请

WO2018129248A1 THERAPEUTIC ANTI-IGE ANTIBODIES AND METHODS AND COMPOSITIONS THEREOF 审中-公开
公开(公告)号：WO2018129248A1
公开(公告)日：2018-07-12
申请号：PCT/US2018/012479
申请日：2018-01-05
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , SIXAL, INC.
发明人： SAXON, Andrew , ZHANG, Ke
IPC分类号： A61K39/00 , A61K39/395 , C07K16/00 , C07K16/42
摘要： Disclosed herein are anti-lgE antibodies having low binding affinity to human IgE and compositions and methods thereof. In some embodiments, the present invention provides a composition comprising one or more humanized low affinity anti-lgE antibodies (hLAAIGEs) and a pharmaceutically acceptable carrier. In some embodiments, the present invention provides a method of treating a subject for an IgE-mediated disorder, which comprises administering to the subject one or more hLAAIGEs or a composition thereof. In some embodiments, the IgE-mediated disorder is an allergic reaction.

9. 发明申请

WO1994021676A1 IgE ISOFORMS AND METHODS OF USE 审中-公开
标题翻译： IgE ISOFORMS和使用方法
公开(公告)号：WO1994021676A1
公开(公告)日：1994-09-29
申请号：PCT/US1994003243
申请日：1994-03-24
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
发明人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , SAXON, Andrew , ZHANG, Ke , MAX, Edward, E.
IPC分类号： C07K07/10
CPC分类号： C07K16/00 , A61K38/00 , C07K2317/52
摘要： Methods and compositions are provided relating to novel IgE isoforms and their use in immune hypersensitivity diagnosis and treatment. The compositions include transcription and translation products of the immunoglobulin epsilon locus, specific probes for epsilon transcription products, and compounds which specifically bind epitopes of epsilon translation products. Novel products of the epsilon locus include the following transcription products and translation products thereof: CH4-M2" (SEQ ID NO:02, residues 1-107 and SEQ ID NO:06), CH4'-CH5-M1'-M2 (SEQ ID NO:02, residues 1-72, SEQ ID NO:03 and SEQ ID NO:05), CH4'-CH5-M2' (SEQ ID NO:02, residues 1-72, SEQ ID NO:03 and SEQ ID NO:07) and CH4'-CH5-M2" (SEQ ID NO:02, residues 1-72, SEQ ID NO:03 and SEQ ID NO:06). Such epsilon products, specific probes and binding compounds find use in methods and kits for immune hypersensitivity diagnosis and treatment.
摘要翻译：提供了关于新型IgE同种型及其在免疫超敏反应诊断和治疗中的应用的方法和组合物。组合物包括免疫球蛋白ε位点的转录和翻译产物，ε转录产物的特异性探针和特异性结合ε翻译产物表位的化合物。 ε位点的新产物包括以下转录产物及其翻译产物：CH4-M2“（SEQ ID NO：02，残基1-107和SEQ ID NO：06），CH4'-CH5-M1'-M2（SEQ SEQ ID NO：02，残基1-72，SEQ ID NO：03和SEQ ID NO：05），CH4'-CH5-M2'（SEQ ID NO：02，残基1-72，SEQ ID NO：03和SEQ ID NO： NO：07）和CH4'-CH5-M2“（SEQ ID NO：02，残基1-72，SEQ ID NO：03和SEQ ID NO：06）。这种ε产品，特异性探针和结合化合物可用于免疫超敏反应诊断和治疗的方法和试剂盒。

10. 发明申请

WO2021232287A1 MODIFYING RADIO ACCESS TECHNOLOGY (RAT) SELECTION PRIORITIES USED BY USER EQUIPMENT (UE) FOR ESTABLISHING WIRELESS CONNECTION 审中-公开
公开(公告)号：WO2021232287A1
公开(公告)日：2021-11-25
申请号：PCT/CN2020/091309
申请日：2020-05-20
申请人： QUALCOMM INCORPORATED , LIU, GuoJing , WANG, Dongsheng , HUI, ChaoFeng , LU, Xiaomeng , CHEN, Xuesong , ZHANG, Fojian , DONG, Wei , SHI, Dunfa , ZHANG, Ke , DUAN, Wenbo , TIAN, Jinglei
发明人： LIU, GuoJing , WANG, Dongsheng , HUI, ChaoFeng , LU, Xiaomeng , CHEN, Xuesong , ZHANG, Fojian , DONG, Wei , SHI, Dunfa , ZHANG, Ke , DUAN, Wenbo , TIAN, Jinglei
IPC分类号： H04W48/20
摘要： This disclosure provides systems, methods, and apparatus, including computer programs encoded on computer-readable media, for modifying wireless wide area network (WWAN) radio access technology (RAT) selection priorities. In some aspects, a user equipment (UE) may determine to access WWAN RAT selection information from a subscriber identification module (SIM) card of the UE. The WWAN RAT selection information may include multimode system selection (MMSS) information. The UE may determine the WWAN RAT selection information indicates a Long-Term Evolution (LTE) RAT has a lower selection priority than one or more legacy RATs, or the UE may determine the WWAN RAT selection information is invalid. The UE may assign a higher selection priority to the LTE RAT than to the one or more legacy RATs. The UE may establish a wireless connection with the LTE RAT in response to assigning the higher selection priority to the LTE RAT.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式